Saniona has entered into a drug discovery and development collaboration with Luc Therapeutics. The collaboration focuses on research of new small molecule therapeutics for treatment of ataxia. Ataxia is a generic term for a group of orphan genetic disorders termed hereditary ataxias. These diseases are characterized by dysfunction or degeneration of the cerebellum – the brain’s coordination center. Patients with these conditions develop severe difficulties walking, speaking, and performing daily activities. Therefore, these debilitating set of conditions severely affect quality and duration of life. The Ataxia-program represents the first targeted pan-ataxia treatment to this grossly underserved patient population. The program is in the late drug discovery phase.